Stock Report

All about this stock under one free report Last Updated: 31-Aug-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

Omnicell Inc. ($0.001 par value) (OMCL) Peer Comparison

Stock Card factsheet share-fund-plan-icon

$33.08

up-down-arrow $-0.33 (-0.99%)

As on 28-Aug-2026 16:00EDT

Market cap

info icon

$1,504 Mln

Revenue (TTM)

info icon

$1,247 Mln

P/E Ratio

info icon

39.9

P/B Ratio

info icon

1.2

Div. Yield

info icon

0 %

Edit peer-selector-edit
Omnicell Inc. ($0.001 par value) (OMCL) Penumbra (PEN) Glaukos Corp (GKOS) Repligen (RGEN) Bio-Rad Laboratories
Market cap ($ Mln)
 1,504 12,753 10,906 9,948 9,762
Revenue ($ Mln)
 1,247 1,505 613 785 2,589
Net Profit ($ Mln)
 39.08 160.59 -188.05 41.54 222.40
Net Margin (%)
 3.13 10.67 -30.68 5.29 8.59
RoE (%)
 3.10 10.86 -28.10 1.97 3.04
Price to Earnings
 39.86 79.35 -- 251.81 44.47
Price-To-Book
 1.18 8.41 16.38 4.86 1.26

Income Statement ($ Mln)

Omnicell Inc. ($0.001 par value) (OMCL) Penumbra (PEN) Glaukos Corp (GKOS) Repligen (RGEN) Bio-Rad Laboratories
Operating Revenue arrow
1,246.70 1,504.87 612.84 785.10 2,589.30
Cost of Revenue arrow
688.58 483.98 127.96 384.30 1,245.50
Gross Profit arrow
508.04 942.44 393.22 347.62 1,343.60
Operating Expenses arrow
499.17 833.56 565.37 335.50 1,108.90
Operating Profit (EBIT) arrow
58.96 187.34 -80.49 65.30 235.00
Other Income arrow
0.00 0.00 0.00 0.00 0.00
Profit before Tax arrow
61.14 203.83 -192.83 52.15 350.40
Provision for Tax arrow
22.06 43.24 -4.79 10.61 128.00
Profit after Tax (Net Income) arrow
39.08 160.59 -188.05 41.54 222.40
Minority Interest arrow
0.00 0.00 0.00 0.00 0.00
Consolidated Profit arrow
0.00 93.19 0.00 0.00 0.00

Liabilities ($ Mln)

Omnicell Inc. ($0.001 par value) (OMCL) Penumbra (PEN) Glaukos Corp (GKOS) Repligen (RGEN) Bio-Rad Laboratories
Shareholder's Funds arrow
1,291.61 1,530.77 682.49 2,112.03 7,173.90
Minority Interest arrow
0.00 0.00 0.00 0.00 0.00
Non-Current Liabilities arrow
259.81 210.18 135.71 705.49 2,116.80
Current Liabilities arrow
447.44 233.78 102.33 132.66 961.30
Total Liabilities arrow
1,974.72 1,826.52 893.49 2,949.70 10,576.50

Assets ($ Mln)

Omnicell Inc. ($0.001 par value) (OMCL) Penumbra (PEN) Glaukos Corp (GKOS) Repligen (RGEN) Bio-Rad Laboratories
Non-Current Assets arrow
1,263.47 630.60 404.74 1,749.63 7,231.50
Current Assets arrow
735.39 1,344.12 515.78 1,200.55 3,020.50
Total Assets arrow
1,974.72 1,826.52 893.49 2,949.70 10,576.50
Total Debt* arrow
200.00 212.71 102.84 690.94 1,203.70
Net Current Assets arrow
287.95 1,110.35 413.45 1,067.90 2,059.20

Cashflow ($ Mln)

Omnicell Inc. ($0.001 par value) (OMCL) Penumbra (PEN) Glaukos Corp (GKOS) Repligen (RGEN) Bio-Rad Laboratories
Cash From Operating Activities arrow
127.30 238.66 -46.34 117.42 532.20
Cash Flow from Investing Activities arrow
-60.36 -404.59 -77.61 -298.47 -189.70
Cash from Financing Activities arrow
-218.32 26.53 11.89 -15.21 -283.20
Net Cash Inflow / Outflow arrow
-- -- -- -- --

Ratios

Profitability Ratios

 Omnicell Inc. ($0.001 par value) (OMCL) Penumbra (PEN) Glaukos Corp (GKOS) Repligen (RGEN) Bio-Rad Laboratories
ROCE (%) arrow
0.13 11.76 -22.53 1.79 8.98
ROE (%) arrow
3.10 10.86 -28.10 1.97 3.04
ROA (%) arrow
1.51 7.95 -18.00 1.36 2.02
EBIT Margin (%) arrow
5.05 13.63 -30.58 9.87 -5.99
Net Margin (%) arrow
3.13 10.67 -30.68 5.29 8.59
Cash Profit Margin (%) arrow
0.00 0.00 0.00 0.00 0.00

Growth Ratios

 Omnicell Inc. ($0.001 par value) (OMCL) Penumbra (PEN) Glaukos Corp (GKOS) Repligen (RGEN) Bio-Rad Laboratories
Revenue Growth (%) arrow
8.45 17.55 41.55 16.49 1.37
EBIT Growth (%) arrow
60.93 17.49 -116.42 920.91 -131.06
Net Profit Growth (%) arrow
69.28 8.72 -102.66 400.42 -30.32
EPS Growth (%) arrow
70.33 8.12 -96.88 394.30 -29.66
Book Value Growth (%) arrow
4.11 17.33 -12.65 2.16 2.19

Valuation Ratios

 Omnicell Inc. ($0.001 par value) (OMCL) Penumbra (PEN) Glaukos Corp (GKOS) Repligen (RGEN) Bio-Rad Laboratories
Price / Earnings arrow
992.52 68.93 -34.59 189.42 --
Price / Book Value arrow
1.18 8.58 9.90 4.86 --
Dividend Yield (%) arrow
0.00 -- -- 0.00 --
EV/EBITDA arrow
14.12 53.25 -43.50 81.02 --
Market Cap ($ Cr) arrow
-- -- -- -- --

Solvency Ratios

 Omnicell Inc. ($0.001 par value) (OMCL) Penumbra (PEN) Glaukos Corp (GKOS) Repligen (RGEN) Bio-Rad Laboratories
Debt to Equity arrow
0.13 0.00 0.00 0.26 0.11
Short term debt to equity ratio arrow
0.01 0.01 0.00 0.01 0.06
Current Ratio arrow
1.64 5.75 5.04 9.05 3.14
Quick Ratio arrow
1.43 3.86 4.46 7.64 2.33
Interest Coverage arrow
16.49 157.91 -38.31 3.36 8.18

Operating Efficiency Ratios

 Omnicell Inc. ($0.001 par value) (OMCL) Penumbra (PEN) Glaukos Corp (GKOS) Repligen (RGEN) Bio-Rad Laboratories
Debtors to sales (%) arrow
18.21 12.65 22.67 20.09 17.06
Asset Turnover arrow
0.48 0.74 0.59 0.26 0.24
Receivable days arrow
72.94 46.54 60.95 72.41 65.39
Inventory Days arrow
51.15 331.92 193.84 146.53 221.09
Payable days arrow
25.84 26.16 60.19 29.05 37.02
Cash Conversion Cycle arrow
98.25 352.30 194.60 189.88 249.46
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...